ADSTILADRIN is an innovative therapy that we believe will transform the current standard of care for these patients, providing an effective alternative therapy.” ...

ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the FDA for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...

Patients who had BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and were urinary minimal residual disease (uMRD)-negative after treatment of Adstiladrin (nadofaragene firadenovec) did not ...

The U.S. Food and Drug Administration has approved Adstiladrin, which is being billed as the first gene therapy treating high-risk, non-muscle-invasive bladder cancer. Adstiladrin is a non-replicating ...

Adstiladrin ® (nadofaragene firadenovec-vncg) is now fully available for the treatment of adults with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer ...

PARSIPPANY, N.J., February 12, 2025--First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary Cancers Symposium ...

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk ...

Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association First results from a Phase 3 trial conducted across 25 ...

Recently, the FDA approved Adstiladrin, the first gene therapy for bladder cancer. It's for patients whose cancer returns after the standard treatment BCG, Bacillus Calmette-Guerin.

Patients and Consumers: For more information about ADSTILADRIN, please visit www.ADSTILADRIN.com, or call 1-888-FERRING (888-337-7464), and select option number one.

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial ( NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN ® (nadofaragene firadenovec-vncg) in ...

ADSTILADRIN has been studied in a clinical trial program that includes 157 patients with high-risk, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit ...